WO/2009/050506 is referenced by 38 patents.

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More 5 specifically the present invention relates to; a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor; a combination product, as defined herein, comprising a kit of parts comprising a MEK inhibitor and a mTOR-selective inhibitor; use of the combination product, as defined herein, in the treatment of cancer; a method of treating cancer comprising administering the combination product, as defined 10 herein, to a patient. The combination product, as defined herein, and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or mTOR.

Title
Combination 059
Application Number
PCT/GB2008/050936
Publication Number
2009/050506
Application Date
October 13, 2008
Publication Date
April 23, 2009
Inventor
Smith Paul David
Agent
GLOBAL INTELLECTUAL PROPERTY
Assignee
Smith Paul David
Astrazeneca
Astrazeneca
IPC
C07D 239/70
A61P 35/00
A61K 45/06
A61K 31/519
A61K 31/4184
View Original Source